Hot Stocks: Brokerages view on Aurobindo Pharma, Apollo Hospitals, Suzlon & Titan Company
Top brokerage firms like Macquarie maintained an outperform rating on Aurobindo Pharma, raising the target price to Rs 1,385. Aurobindo Pharma signed a master service agreement with Merck Sharp & Dohme, leading to a biologics CMO contract with TheraNym.
Brokerage maintained an rating on , initiated coverage on , upgraded Apollo Hospital and CLSA maintained a buy rating on .We have collated a list of from top from ETNow and other sources:
Macquarie on Aurobindo Pharma: Outperform | Target Rs 1,385
Macquarie maintained an outperform rating on Aurobindo Pharma but raised the target price to Rs 1,385 from Rs 1,300 earlier.
The company announced the signing of a master service agreement with Merck Sharp & Dohme. It is the first of its kind biologics CMO contract from a large pharma company.
TheraNym will invest - Rs 1,000 crore and build a manufacturing facility. The global investment bank believes the actual revenue from the contract would start flowing from CY27.
It opens up the possibility to contract with other large pharma companies seeking to move their supply chains out of China. The global investment bank raised FY25E/26E earnings estimates by 1% each.
Morgan Stanley on Suzlon: Overweight| Target Rs 58.50
Morgan Stanley initiated coverage on Suzlon with an overweight rating and a target of Rs 58.50. Suzlon 2.0 is well positioned to benefit from energy transition.
The market has not fully appreciated growth potential yet. Earnings are likely to grow at 57% CAGR in FY 24-27.
CLSA on : Outperform| Target Rs 7,150
CLSA upgraded Apollo Hospitals to outperform from buy earlier and has also raised the target price to Rs 7,150 from Rs 7,000 earlier.
Capping rates will be difficult to implement. The recent decline in the stock price is unwarranted.
CLSA on Titan Company: Buy| Target Rs 4,270
CLSA maintained a buy rating on Titan Company and raised the target price to Rs 4,270 from Rs 4,045 earlier.
The company delivered strong revenue growth guidance dampened by slightly weaker margins. However, Titan raised the upper limit of its growth targets for jewellery.
Titan lowered the margin band by 50 bps to 11.5%-12.5% for the jewellery business. The company is best placed to benefit from rising affluence and premiumization.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Macquarie maintained an outperform rating on Aurobindo Pharma but raised the target price to Rs 1,385 from Rs 1,300 earlier.
The company announced the signing of a master service agreement with Merck Sharp & Dohme. It is the first of its kind biologics CMO contract from a large pharma company.
TheraNym will invest - Rs 1,000 crore and build a manufacturing facility. The global investment bank believes the actual revenue from the contract would start flowing from CY27.
It opens up the possibility to contract with other large pharma companies seeking to move their supply chains out of China. The global investment bank raised FY25E/26E earnings estimates by 1% each.
Morgan Stanley on Suzlon: Overweight| Target Rs 58.50
Morgan Stanley initiated coverage on Suzlon with an overweight rating and a target of Rs 58.50. Suzlon 2.0 is well positioned to benefit from energy transition.
The market has not fully appreciated growth potential yet. Earnings are likely to grow at 57% CAGR in FY 24-27.
CLSA on : Outperform| Target Rs 7,150
CLSA upgraded Apollo Hospitals to outperform from buy earlier and has also raised the target price to Rs 7,150 from Rs 7,000 earlier.
Capping rates will be difficult to implement. The recent decline in the stock price is unwarranted.
CLSA on Titan Company: Buy| Target Rs 4,270
CLSA maintained a buy rating on Titan Company and raised the target price to Rs 4,270 from Rs 4,045 earlier.
The company delivered strong revenue growth guidance dampened by slightly weaker margins. However, Titan raised the upper limit of its growth targets for jewellery.
Titan lowered the margin band by 50 bps to 11.5%-12.5% for the jewellery business. The company is best placed to benefit from rising affluence and premiumization.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Source: Stocks-Markets-Economic Times
